H8H-MC-LAHW: A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506724-85-00

Acronym

H8H-MC-LAHW

Enrollment

175

Registered

2023-09-07

Start date

2020-11-19

Completion date

2025-12-04

Last updated

2025-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

Percentage of Treatment Emergent Adverse Events (TEAEs) by Treated Migraine Attack, Percentage of Participants with Discontinuations Due to Adverse Events (AEs)

Interventions

DRUGLASMIDITAN

DRUGLasmitidan

DRUGLasmiditan

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Percentage of Treatment Emergent Adverse Events (TEAEs) by Treated Migraine Attack, Percentage of Participants with Discontinuations Due to Adverse Events (AEs)	—

Countries

Belgium, France, Germany, Italy, Netherlands, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026